News | March 17, 2024
Eris Lifesciences buys India formulation business of Biocon Biologics for Rs. 1,242 Cr
Both organisations enter into a long- term collaboration to expand patient access in India
Both organisations enter into a long- term collaboration to expand patient access in India
This agreement paves the way for the introduction of YESAFILI into the Canadian market
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
10+ emerging markets, Japan & ANZ transition in final phase
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
The centralized marketing authorization granted by the EC is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway
The RCSed's Court of Regents comprises a group of distinguished and accomplished individuals in their field
Biocon Biologics recently acquired the global biosimilars business of its long-term partner Viatris
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)